Evidence Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Sep 9, 2025; 14(3): 105731
Published online Sep 9, 2025. doi: 10.5409/wjcp.v14.i3.105731
Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease
Rahiya Rehman
Rahiya Rehman, Department of Pediatric Gastroenterology, Saint Louis University, Saint Louis, MO 63108, United States
Author contributions: Rehman R wrote the manuscript, thoroughly reviewed, and endorsed the final manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rahiya Rehman, MD, Assistant Professor, Department of Pediatric Gastroenterology, Saint Louis University, 1465 S Grand Blvd, Saint Louis, MO 63108, United States. rahiya.rehman@health.slu.edu
Received: February 5, 2025
Revised: March 4, 2025
Accepted: April 14, 2025
Published online: September 9, 2025
Processing time: 131 Days and 15.4 Hours
Core Tip

Core Tip: Understanding the impact of glucagon-like peptide-1 analogs in the pediatric population is crucial, as these medications have the potential to address a significant treatment gap in childhood metabolic disorders. Their effects on weight regulation, insulin sensitivity, and liver health could offer long-term benefits, particularly in condiBeltagi, MD, PhD, Chief Physician, Professortions such as obesity, type 2 diabetes, and metabolic dysfunction associated steatotic liver disease. Further research and clinical trials are needed to establish their safety, efficacy, and appropriate use in children.